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ABSTRACT
Objective Retinal nerve ﬁbre layer (RNFL) thickness is
related to the axonal anterior visual pathway and is
considered a marker of overall white matter ‘integrity’.
We hypothesised that RNFL changes would occur in
people with epilepsy, independently of vigabatrin
exposure, and be related to clinical characteristics of
epilepsy.
Methods Three hundred people with epilepsy
attending specialist clinics and 90 healthy controls were
included in this cross-sectional cohort study. RNFL
imaging was performed using spectral-domain optical
coherence tomography (OCT). Drug resistance was
deﬁned as failure of adequate trials of two antiepileptic
drugs to achieve sustained seizure freedom.
Results The average RNFL thickness and the thickness
of each of the 90° quadrants were signiﬁcantly thinner
in people with epilepsy than healthy controls (p<0.001,
t test). In a multivariate logistic regression model, drug
resistance was the only signiﬁcant predictor of abnormal
RNFL thinning (OR=2.09, 95% CI 1.09 to 4.01,
p=0.03). Duration of epilepsy (coefﬁcient −0.16,
p=0.004) and presence of intellectual disability
(coefﬁcient −4.0, p=0.044) also showed a signiﬁcant
relationship with RNFL thinning in a multivariate linear
regression model.
Conclusions Our results suggest that people with
epilepsy with no previous exposure to vigabatrin have a
signiﬁcantly thinner RNFL than healthy participants.
Drug resistance emerged as a signiﬁcant independent
predictor of RNFL borderline attenuation or abnormal
thinning in a logistic regression model. As this is easily
assessed by OCT, RNFL thickness might be used to
better understand the mechanisms underlying drug
resistance, and possibly severity. Longitudinal studies are
needed to conﬁrm our ﬁndings.
INTRODUCTION
The retinal nerve ﬁbre layer (RNFL) contains glia
and the unmyelinated axons of retinal ganglion
cells. As retinal axons are devoid of myelin until
they penetrate the lamina cribrosa, the evaluation
of RNFL thickness has been suggested as a method
of assessing axonal ‘integrity’ in the anterior visual
pathway and the white matter tracts throughout the
central nervous system.
1 Optical coherence tomog-
raphy (OCT) is a reproducible and non-invasive
technique for cross-sectional imaging of retinal
microstructure and has enabled high-resolution
quantiﬁcation of RNFL thickness. OCT has been
successfully used to evaluate axonal injury and
disease progression in a number of neurological
conditions.
2 In epilepsy, we previously reported a
strong linear relationship between RNFL thickness
and visual ﬁeld size in people with a history of vig-
abatrin exposure.
3 Only one other study has
explored RNFL and macular thickness in epilepsy,
in adolescents with newly diagnosed epilepsy
before and during monotherapy with either val-
proic acid or carbamazepine over 1 year duration:
no difference was detected.
4 Widespread white
matter involvement has already been shown in epi-
leptogenesis,
5 and in seizure-related degeneration
associated with progressive cognitive decline in epi-
lepsy.
6 Diffusion tensor imaging and volumetric
MRI have demonstrated abnormalities in white
matter integrity in people with temporal lobe epi-
lepsy.
7–9 Widespread neuronal degeneration is also
seen in chronic human epilepsy,
10 and in most
animal models of focal epileptogenesis in the
immature and adult brain,
11 suggesting the exist-
ence of a disordered ‘connectome’.
91 2We postu-
lated that there are common biological mechanisms
leading to both neuronal degeneration and RNFL
changes in people with epilepsy. We therefore
hypothesised that RNFL thinning would occur in
epilepsy, independent of previous vigabatrin treat-
ment, and would be associated with clinical and
neuroradiological features of epilepsy.
METHODS
Participants
Four hundred and ﬁfty-four people with epilepsy
able to undertake OCTwere consecutively included
in this cross-sectional cohort study. People were
recruited from tertiary care clinics at the National
Hospital for Neurology and Neurosurgery from
September 2008 to August 2013. Demographic
and clinical data were obtained from medical
records. Participants were excluded from the ana-
lyses if they had previous exposure to vigabatrin,
diabetes, glaucoma or other known ocular disease,
concurrent diagnosis of multiple sclerosis, history
of trauma or surgery to the eye or orbit, a distance
refractive error of >4.50 dioptres mean sphere/
>2.5 dioptres cylinder, brain MRI evidence of
visual pathway involvement (deﬁned as damage to
the optic nerve, chiasm or tract, to the lateral gen-
iculate nucleus, to the optic radiations or to the
primary or association visual cortices, of traumatic,
vascular or inﬂammatory origin as determined by
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cipants were recruited from May 2010 to August 2013; the con-
trols also met relevant inclusion and exclusion criteria.
Clinical data
The following variables were evaluated: age, sex, ethnicity, epi-
lepsy diagnosis,
13 duration of epilepsy (from the time of diagno-
sis to the date of OCT assessment), handedness, intellectual
disability, antiepileptic drug (AED) history, epilepsy surgery,
presence of VNS (vagus nerve stimulator, active or switched
off). Intellectual disability was deﬁned as an IQ<70 from a pre-
vious psychometric assessment, with onset under 18 years of
age, or systematic mention (on at least two occasions) of ‘learn-
ing/intellectual disability’ or ‘mental retardation’ in the medical
notes. Drug resistance was assessed at the time of OCT assess-
ment and deﬁned as previous failure of adequate trials of two
tolerated, appropriately chosen and used AED schedules
(whether as monotherapies or in combination) to achieve sus-
tained (>12 months) seizure freedom.
14 Anyone who had had
therapeutic neurosurgical resection for the treatment of epilepsy
was considered drug-resistant irrespective of outcome, in
keeping with convention. People who did not meet criteria for
being classed as drug-resistant were labelled as ‘not-resistant’.
We also considered the total number of AEDs to which each
person was currently, and ever had been, exposed.
Optical coherence tomography
All participants were assessed using spectral-domain OCT
(Cirrus OCT; Carl Zeiss Meditec, USA), by six experienced
operators. Intraobserver and interobserver reproducibility were
excellent (see online supplementary data S1–S2). Average RNFL
thickness in the peripapillary area and the four 90° quadrants
(temporal, nasal, superior and inferior) was measured. The auto-
mated report gave the percentile into which the RNFL thickness
fell, based on the manufacturer’s internal database of age-
corrected normal values.
15 The scan was considered normal if
the values obtained were between the 5th and 95th centiles,
borderline if between 1st and 5th, and abnormally thinned if
<1st centile (ﬁgure 1). Only data from the right eye were ana-
lysed (see online supplementary data S3).
MRI
Brain MRIs performed within a 12-month interval before or
after OCT were evaluated. This time span was a pragmatic
choice given previous evidence of an average of 0.92% total
brain volume loss, 0.80% grey matter volume loss and 1.11%
white matter volume loss over a 3.5 year period in 179 people
with epilepsy versus an average of 0.49% total brain volume
loss, 0.31% grey matter volume loss and 0.71% white matter
volume loss over the same follow-up period in 90 healthy con-
trols.
16 MRI acquisition and analysis are described in online
supplementary data S4.
Statistics
Data were analysed using Stata/IC V .11.1 (Stata, Texas, USA).
t test and Pearson χ
2 test were used to compare demographic
data between cases and controls. Comparison of the distribution
of average RNFL thickness, considered both as a continuous
variable and as a categorical variable, between cases and con-
trols, was performed by t test and Pearson χ
2, with a
Bonferroni-adjusted p<0.05 signiﬁcance level. Thereafter, only
the group of people with epilepsy was analysed. t test, analysis
of variance (ANOVA) and Pearson’s correlation coefﬁcient were
used to test for differences in the distribution of average RNFL
thickness as a continuous variable according to each demo-
graphic and clinical factor, considered independently. To iden-
tify independent predictors of RNFL changes, the average
RNFL thickness was considered as the dependent variable in a
multivariate linear regression model, using a backward-stepwise
approach. The multivariate regression model was constructed
after adjusting for potential confounding factors, considered as
the variables that emerged as signiﬁcant (p<0.05) in the uni-
variate analyses. To identify signiﬁcant independent predictors
of borderline attenuation or abnormal thinning of the RNFL, a
multivariate logistic regression model, using a backward-
stepwise approach and considering the presence of RNFL thin-
ning below 5th centile as the dependent variable was generated.
We estimated ORs and 95% CIs. Variables with high collinearity
(variance inﬂation factor >5) were excluded from the multivari-
ate model. The set of people with available MRI was divided
into two groups according to scan state (normal or abnormal—
see online supplementary table S1). Analysis of correlation
between average RNFL thickness, sex, duration of epilepsy and
neuroimaging volumetric data was ﬁrst performed in the two
subgroups and then in the entire subset (Pearson’s correlation,
Bonferroni correction for sex and duration).
Standard protocol approvals, registrations and consent
This study was approved by the institutional ethics committee.
All participants provided written informed consent.
RESULTS
Three hundred of the 454 people scanned met inclusion criteria
(exclusions listed in online supplementary data S5). Their scans
were analysed and compared to results from 90 healthy con-
trols. Most people had drug-resistant epilepsy (210 individuals,
72.2%) and long disease duration (mean 23.3 years, SD 15.1).
Demographic and clinical data are presented in online supple-
mentary table S2.
RNFL thickness in people with epilepsy compared with
healthy controls
The average RNFL thickness and the thickness of each 90°
quadrant were signiﬁcantly lower in people with epilepsy than
in healthy controls (table 1): 12.7% had abnormal average
RNFL thinning (≤1st centile), with 17.0% having borderline
changes (≤5th to >1st centile). RNFL thinning ≤1st centile, or
>1st to 5th centile, was most frequently seen in the superior
and inferior quadrants (table 2). As expected, ≥95% of healthy
controls showed normal average and 90° quadrant RNFL thick-
ness (>5th centile). No control had abnormal RNFL thinning
(<1st centile) for average RNFL thickness or for any 90°
quadrant.
Average RNFL thickness and clinical characteristics—
univariate associations
We found a correlation between smaller average RNFL thickness
and increasing age (Pearson’s correlation coefﬁcient −0.18;
p<0.001) and epilepsy duration (Pearson’s correlation coefﬁ-
cient −0.14; p=0.015), with both age and duration directly cor-
related with each other (Pearson’s correlation coefﬁcient 0.62;
p<0.001). Age was not correlated with RNFL thickness in the
modest number of healthy controls (Pearson’s correlation coefﬁ-
cient 0.01; p=0.919). Average RNFL thickness was greater in
females (88.8 mm±14.0 SD) than males (85.5 mm±13.3 SD;
p=0.021, t test). People with epilepsy and intellectual disability
had thinner average RNFL (83 mm±12.5 SD) than those with
normal intellectual function (86.1 mm±14.8 SD; p=0.049,
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thickness according to handedness (p=0.523, ANOVA), epilepsy
type (p=0.219, ANOVA) or ethnicity (p=0.436, ANOVA).
Average RNFL thickness across all quadrants and exposure
to AEDs or non-medical treatments
Average RNFL thinning was associated with exposure to the
following individual AEDs (correlation analysis, uncorrected
p values): ethosuximide, phenytoin, primidone, sodium valpro-
ate and topiramate. The effect of different AED combinations
on RNFL thickness was not tested. The presence of VNS (either
active or switched off) was also associated with thinner average
RNFL thickness. Previous surgical treatment for epilepsy
(n=31) was not associated with a signiﬁcantly thinner RNFL
(see online supplementary table S3). However, operated patients
had thinner average RNFL (82.5 mm±15.7 SD) than healthy
controls (95.3 mm±8.8 SD; p<0.001, t test). The interval
between the surgical treatment to OCT scan was not signiﬁ-
cantly correlated with the RNFL thickness in this small sample
of 31 operated cases (Pearson’s correlation coefﬁcient −0.09;
p=0.647). There was no signiﬁcant correlation between the
average RNFL thickness and the total number of AEDs taken
(Pearson’s correlation coefﬁcient −0.09; p=0.154). People with
drug-resistant epilepsy had thinner average RNFL (84.2 mm
±13.9 SD) than people with non-resistant epilepsy (88.1 mm
±15.3 SD; p=0.038, t test), who in turn had thinner average
RNFL than healthy controls (95.3 mm±8.8 SD; p=0.001, t
test). A signiﬁcant association between drug resistance and VNS
implant (p=0.004, Pearson χ
2) was found. In the drug-resistant
group, there were more females (54.8%) than males (45.2%;
p=0.042, Pearson χ
2).
Predictors of RNFL thickness changes in multivariate
regression models
Univariate linear regression analysis showed signiﬁcant associ-
ation between RNFL and: female sex, epilepsy duration, intellec-
tual disability, exposure to ethosuximide, phenytoin, primidone,
valproate or topiramate, VNS implant, and drug-resistant epi-
lepsy. Multivariate linear regression showed signiﬁcant associ-
ation for RNFL thinning only with epilepsy duration, intellectual
disability, drug resistance (adjusted R
2=0.072, p<0.001; table 3)
The residuals of the model were close to a normal distribution
(0.37% low severe outliers, 0.00% high severe outliers; mean
variance inﬂation factor 1.03).
Multivariate logistic regression analysis showed an increased
probability of RNFL thinning (borderline or abnormal) in people
with drug-resistant epilepsy (OR=2.09, CI 95% 1.09 to 4.01,
p=0.027). A global test of goodness-of-ﬁt indicated that the
model ﬁtted the data well (Hosmer and Lemeshow’s goodness-
of-ﬁt test, Pearson χ²=175.45, p=0.497). Neither multivariate
Figure 1 Sample optical coherence tomography report of retinal nerve ﬁbre layer (RNFL) thickness taken from a healthy control with normal visual
ﬁelds showing normal RNFL thickness with an average RNFL thickness of 82 mm in the right eye and 77 mm in the left eye. The average RNFL
thickness and RNFL thickness in each of the 90° quadrants are shown in green as they fall within the ≤95th to ≥5th centile of the normal
distribution percentiles provided by the manufacturer’s inbuilt database.
Table 1 RNFL thickness, considered as continuous variable, in
people with epilepsy and in healthy controls
Average RNFL
thickness, mm
People with
epilepsy
Healthy
controls
Significance of
difference (t test),
p Value
Average RNFL
thickness across all 4
quadrants, mean±SD
85.4±14.3 95.3±8.8 <0.001
Superior quadrant 103.4±22.4 115.3±10.6 <0.001
Nasal quadrant 68.9±14.7 77.7±13.9 <0.001
Inferior quadrant 107.8±24.1 122.8±14.5 <0.001
Temporal quadrant 61.4±13.6 65.2±10.2 0.016
RNFL, retinal nerve fibre layer.
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AEDs in place of drug resistance showed an association.
Correlation between average RNFL thickness and MRI brain
volumes
Of 300 people with epilepsy, 211 had an MRI performed
within±12 months of OCT (median 0 days; range −304 to
+350). Thirty-nine scans were excluded due to poor segmenta-
tion or lack of a T1-weighted volumetric (three-dimensional)
sequence; 172 MRIs were included (107 interpreted as normal,
65 as abnormal, listed in online supplementary table S1).
Results are given in online supplementary table S4. In 107
people with epilepsy and normal MRI, we found a signiﬁcant
association between RNFL thickness and brain parenchymal
fraction, independent of sex and duration of epilepsy (Pearson’s
correlation, p=0.010; see online supplementary ﬁgure S1). This
association was also observed in the group of people with epi-
lepsy and abnormal MRI, after correcting for sex and duration
of epilepsy (Pearson’s correlation, p=0.045). There was also an
overall association between average RNFL thickness and grey
matter fraction (Pearson’s correlation, p=0.022), which was not
seen in the two subgroups with normal (Pearson’s correlation,
p=0.175) and abnormal (Pearson’s correlation, p=0.545) MRI.
DISCUSSION
We demonstrate that individuals with epilepsy on treatment, but
not exposed to vigabatrin, have a thinner RNFL thickness than
healthy participants. RNFL thinning is associated with longer
duration of epilepsy, presence of drug resistance and intellectual
disability. In the subset of people with epilepsy and available
MRI data, brain parenchymal fraction shows a direct linear
association with the average RNFL thickness. Only drug resist-
ance emerges as a signiﬁcant independent predictor of border-
line attenuation or abnormal thinning of the RNFL in a logistic
regression model. People with drug-resistant epilepsy have a
more than twofold odds of RNFL thinning compared with
people with non-resistant epilepsy.
The biological mechanisms leading to the association between
RNFL changes and intellectual disability, lower brain parenchy-
mal fraction or drug resistance are unknown. Retina and brain
share common embryonic origin and patterns of gene expres-
sion.
17 A physical association between these two structures of
neuroectodermal origin is also manifest through trans-synaptic
degeneration, a process occurring when damage spreads from
posterior to anterior visual pathway or vice versa, described in
several central nervous system diseases, with neuronal damage
caused by a focal brain lesion affecting the function and morph-
ology of remote, apparently intact, regions following interrup-
tion of brain circuits.
18 In people with temporal lobe epilepsy,
trans-synaptic degeneration of the limbic system or extratem-
poral areas has been demonstrated using MRI, positron emission
tomography and single-photon emission CT imaging.
19
Widespread white and grey matter involvement has already been
shown in epilepsy.
10–11 20 Evidence of trans-synaptic degener-
ation in the human central nervous system has already been
shown in previous studies using OCT.
21 22 These links may
underpin the observed associations between RNFL thinning and
various measures, structural (eg, brain parenchymal fraction)
and functional (intellectual disability, drug resistance).
Several previous studies have suggested that RNFL thickness
reﬂects cerebral axonal integrity.
23 24 Given the association
between RNFL thickness and brain parenchymal fraction (brain
Table 2 RNFL thickness, considered as categorical variable according to the normal distribution percentiles provided by the manufacturer’s
inbuilt database, in people with epilepsy and in healthy controls
People with epilepsy Healthy controls
Significance of difference
(Pearson χ
2), p Value* Average RNFL thickness, mm N (%) B (%) A (%) N (%) B (%) A (%)
Average RNFL thickness across all 4 quadrants 70.3 17.0 12.7 95.5 4.5 0.0 <0.001
Superior quadrant 71.6 9.3 19.1 100 0.0 0.0 <0.001
Nasal quadrant 89.9 5.4 4.7 97.7 2.3 0.0 0.018
Inferior quadrant 71.6 12.4 16.0 98.9 1.1 0.0 <0.001
Temporal quadrant 88.6 6.0 5.4 96.6 3.4 0.0 0.023
*Comparison of normal versus borderline or abnormal values among the two groups (2×2 table).
A, abnormal (≤1st centile); B, borderline (≤5th to >1st centile); RNFL, retinal nerve fibre layer; N, normal (>5th centile).
Table 3 Univariate and multivariate linear regression analysis considering average RNFL thickness across all quadrants as dependent variable
Variables Univariate coefficient (95% CI) Multivariate coefficient VIF t p Value 95% CI
Epilepsy duration −0.16 (−0.27 to −0.06) −0.17 1.04 −3.01 0.003 −0.27 to −0.06
Intellectual disability −4.49 (−8.38 to −0.59) −3.95 1.03 −2.02 0.048 −7.87 to −0.04
Drug resistance −6.07 (−9.69 to −2.46) −4.89 1.01 −2.65 0.009 −8.52 to −1.25
Female sex 4.19 (0.98 to 7.41) –– – – –
Ethosuximide exposure −7.07 (−13.23 to −0.90) –– – – –
Phenytoin exposure −4.58 (−8.00 to −1.16) –– – – –
Primidone exposure −8.68 (−15.66 to −1.69) –– – – –
Sodium valproate exposure −4.25 (−7.97 to −0.53)
Topiramate exposure −4.45 (−7.74 to −1.17)
VNS implant −11.07 (−17.64 to −4.51)
Constant 94.14 1.94 48.52 <0.001 90.32 to 97.96
RNFL, retinal nerve fibre layer; VIF, variance inflation factor; VNS, vagus nerve stimulator.
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participants)
25 in multiple sclerosis,
23 independent of optic
neuritis,
24 RNFL thickness has been proposed as a marker of
early neurodegenerative processes in multiple sclerosis. Shared
neurodegenerative processes have also been demonstrated in a
mouse model of Alzheimer’s disease, where β-amyloid immu-
noreactive plaques were detected in the retina.
26 RNFL thinning
has been shown in a wide spectrum of neurological and oph-
thalmological conditions, with a highly variable interval from an
acute event or disease onset to thinning, ranging from months
after an acute attack of acute angle closure glaucoma
27 or optic
neuritis
28 to years as, for instance, in multiple sclerosis.
29
Shared neurodegenerative processes may also be present in the
epilepsies. We report, for the ﬁrst time in epilepsy, a signiﬁcant
association between RNFL thinning and lower brain volume as
assessed by brain MRI. This association was maintained after
correcting for sex and duration of epilepsy. From our cross-
sectional study, we cannot determine the reasons for lower brain
parenchymal fraction, but RNFL thickness does seem to reﬂect
this cerebral measure. A cross-sectional relationship may not
yield the strongest correlations since brain atrophy may lag
behind RNFL changes or vice versa. If this association was con-
ﬁrmed in future prospective studies, RNFL thickness could be
advanced as a reliable, inexpensive and easily assessed comple-
mentary surrogate marker for exploration of whole-brain cere-
bral processes, such as potential neurodegenerative processes,
11
in human epilepsy.
Seizures have a number of adverse consequences.
30 Drug
resistance is the label applied when seizures continue to occur
despite treatment. In our analysis, drug resistance is the only
independent predictor of a borderline or abnormal RNFL thick-
ness. One possible explanation is that ongoing seizures cause
cerebral damage that may manifest in lower brain parenchymal
fraction and secondary thinning of RNFL. Longitudinal studies
are now needed to verify this. There are alternative interpreta-
tions, such as the concept of ‘intrinsic epilepsy severity’, which
holds that there are common neurobiological factors underlying
both severity and drug resistance in epilepsy.
31 Developing this
theory, thinner RNFL, smaller brain parenchymal fraction and
presence of intellectual disability might all be part of a more
severe epilepsy condition from outset. Additional effects over
time may further aggravate RNFL thinning. Prospective studies
will be needed to disentangle these various possibilities.
Other associations with RNFL thinning were found: epilepsy
duration, intellectual disability, VNS implant. Epilepsy duration
showed a signiﬁcant linear inverse relationship with RNFL
thickness, though it did not predict abnormal or borderline
RNFL thinning in the logistic multivariate model. Age at exam-
ination was also associated with RNFL thinning in the inde-
pendent association analysis, but was excluded from the
regression models because of high collinearity with epilepsy dur-
ation. A thinner average RNFL was found in people with epi-
lepsy and intellectual disability than in people with epilepsy and
normal intellectual function. The underlying cause of intellec-
tual difﬁculties might also inﬂuence drug responsiveness. In our
analysis, intellectual disability as a variable was extracted from
medical record review and in most cases was conﬁrmed by
formal neuropsychometry. Intellectual disability present in chil-
dren born prematurely has been attributed to injury to the cere-
bral white matter and associated neuronal and axonal
abnormalities.
32 However, when considering RNFL thickness in
children, its association with the development of the anterior
chamber needs to be taken in account and a number of potential
confounding factors have to be considered, including age, axial
eyeball length and refractive status.
33 In studies of individuals
with multiple sclerosis, RNFL thinning was associated with cog-
nitive disability.
34 Similarly, in healthy young individuals, RNFL
thickness was associated with level of cognitive functioning.
35
The association of RNFL thinning with intellectual disability or
cognitive impairment may therefore also reﬂect compromised
white matter integrity.
36 37 VNS implant was signiﬁcantly
related with RNFL thinning in the univariate linear regression
model, probably due to high collinearity with drug-resistant epi-
lepsy. Thinning seems unrelated to syndromic diagnosis, but this
will need to be explored in a larger study testing RNFL thinning
in speciﬁc epilepsy subtypes.
There are limitations to our study. A key caveat is the cross-
sectional design, which cannot ascribe causation. Prospective
studies are needed to evaluate the role of RNFL thickness as a
possible biomarker and to tease out the effects of other factors,
such as the frequency of seizures and the use of speciﬁc AEDs,
some of which have been reported to inﬂuence brain volume or
resilience to injury. We recognise that, using retrospective case
note data not designed for such studies, the dichotomous classi-
ﬁcation into ‘drug-resistant’ and ‘non-resistant’ is an oversimpli-
ﬁcation in absolute terms, but we note that the total number of
drugs tried by the two groups is signiﬁcantly different in the
expected direction, so that any oversimpliﬁcation is unlikely to
have a material impact on our ﬁndings. The study included
fewer controls than cases, though cases and controls were well
matched in terms of age, sex and ethnicity, which are the only
non-pathological factors known to inﬂuence RNFL thickness.
All data were also compared with a larger internal data set from
normal individuals. We note also that while the total number of
people studied was 300, this number included people with all
types of epilepsy. Some syndromes may have a greater propen-
sity for neurodegeneration and white matter volume loss, and
possibly therefore also for RNFL thinning. Though we excluded
participants with known glaucoma, we recognise that glaucoma
might be asymptomatic or undiagnosed. Furthermore, indivi-
duals with intraocular pressure in the normal range might still
have normal-tension glaucoma and RNFL thinning. All these
issues will need further exploration in a larger cohort followed
prospectively.
OCT is a fast, reproducible, non-invasive, well-tolerated and
cost-efﬁcient investigation. When compared with other potential
methods for investigating resistance,
16 38 39 OCT is not subject
to temporal sampling issues like EEG, represents about 5% of
the capital outlay of typical MRI, is much cheaper to run and
can be undertaken and interpreted by easily trained operators. If
conﬁrmed in a prospective study, our ﬁndings might have clin-
ical relevance. RNFL thickness might be considered as an
objective, complementary and repeatable measure of the biology
of drug resistance, and possibly disease severity. Furthermore,
our results provide a basis for a better understanding of mechan-
isms underlying neurodegeneration in epilepsy.
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